首頁 > 市場調查報告書 > 製藥

循環系統

市場調查報告書

商品編碼

1643249

缺血性心臟病藥物市場 - 全球產業規模、佔有率、趨勢、機會和預測，按疾病類別、藥物類別、地區和競爭細分，2020-2030F

Ischemic Heart Disease Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Disease Class, By Drug Class, By Region and Competition, 2020-2030F

出版日期: 2025年01月24日 | 出版商:

TechSci Research | 英文 182 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

2024年全球缺血性心臟病（IHD）藥物市值為59.8億美元，預計2030年將達到75.7億美元，預測期內複合年成長率為4.20%。缺血性心臟病 (IHD)，通常也稱為冠狀動脈疾病 (CAD) 或冠狀動脈心臟病 (CHD)，是一種主要影響心臟及其血管的疾病。它是最常見的心臟病形式，也是心臟病發作和其他心血管事件的主要原因。 IHD 的特徵是心肌供血不足，通常是由於為心臟提供氧氣和營養物質的冠狀動脈狹窄或阻塞所致。心臟是一個肌肉器官，需要持續供應氧氣和營養才能正常運作。這種供應是透過環繞心臟的冠狀動脈網路輸送的。 IHD 的主要原因是動脈粥狀硬化，這是脂肪沉積、膽固醇和其他物質積聚在冠狀動脈內壁的過程。這種積聚形成斑塊，隨著時間的推移，斑塊會使動脈變窄。缺血可引起各種症狀，其中最常見的是胸痛或心絞痛等不適。其他症狀可能包括呼吸急促、疲勞以及放射至頸部、下巴、肩膀、手臂或背部的疼痛。多種危險因子會導致 IHD 的發生，包括高血壓、高膽固醇、糖尿病、吸菸、肥胖、久坐的生活方式和心臟病家族史。持續的研究和開發工作致力於創造新的、更有效的 IHD 藥物，改善治療選擇和結果。對 IHD 早期發現和介入的重視有助於推動對能夠有效控制病情、預防心臟病等併發症的藥物的需求。強力的臨床證據支持 IHD 藥物的功效，包括它們降低心血管事件風險的能力，為它們的使用提供了信心。全球老化人口更容易患 IHD，這增加了患者數量和對 IHD 藥物的需求。遺傳和分子分析的進步帶來了個人化的治療策略，根據個別患者的情況量身訂做藥物治療方案。

市場概況
預測期	2026-2030
2024 年市場規模	59.8億美元
2030 年市場規模	75.7億美元
2025-2030 年複合年成長率	4.20%
成長最快的細分市場	心絞痛
最大的市場	北美洲

主要市場促進因素

藥物開發的進展

加強早期診斷和干涉

人口老化加劇

主要市場挑戰

藥品定價和負擔能力

通用競爭

主要市場趨勢

增加他汀類藥物的使用

細分市場洞察

疾病類型見解

藥品類別見解

區域洞察

Global Ischemic Heart Disease (IHD) Drugs Market was valued at USD 5.98 Billion in 2024 and is expected to reach USD 7.57 Billion by 2030 with a CAGR of 4.20% during the forecast period. Ischemic Heart Disease (IHD), also commonly known as coronary artery disease (CAD) or coronary heart disease (CHD), is a medical condition that primarily affects the heart and its blood vessels. It is the most common form of heart disease and a leading cause of heart attacks and other cardiovascular events. IHD is characterized by the inadequate blood supply to the heart muscle, usually due to the narrowing or blockage of the coronary arteries that supply the heart with oxygen and nutrients. The heart is a muscular organ that requires a constant supply of oxygen and nutrients to function properly. This supply is delivered through a network of coronary arteries that wrap around the heart. The primary cause of IHD is atherosclerosis, a process in which fatty deposits, cholesterol, and other substances build up on the inner walls of the coronary arteries. This buildup forms plaques, which can narrow the arteries over time. Ischemia can cause various symptoms, with chest pain or discomfort known as angina being the most common. Other symptoms may include shortness of breath, fatigue, and pain radiating to the neck, jaw, shoulders, arms, or back. Several risk factors contribute to the development of IHD, including high blood pressure, high cholesterol, diabetes, smoking, obesity, a sedentary lifestyle, and a family history of heart disease. Ongoing research and development efforts lead to the creation of new and more effective IHD drugs, improving treatment options and outcomes. The emphasis on early detection and intervention in IHD helps drive the demand for medications that can effectively manage the condition, preventing complications like heart attacks. The availability of robust clinical evidence supporting the efficacy of IHD drugs, including their ability to reduce the risk of cardiovascular events, provides confidence in their use. The global aging population is more susceptible to IHD, which increases the patient pool and the need for IHD drugs. Advancements in genetic and molecular profiling have led to personalized treatment strategies, tailoring medication regimens to individual patient profiles.

Market Overview
Forecast Period	2026-2030
Market Size 2024	USD 5.98 Billion
Market Size 2030	USD 7.57 Billion
CAGR 2025-2030	4.20%
Fastest Growing Segment	Angina Pectoris
Largest Market	North America

Key Market Drivers

Advancements in Drug Development

Pharmaceutical companies and research institutions have been working on the development of novel therapies, including medications with unique mechanisms of action. For example, sodium-glucose co-transporter 2 (SGLT2) inhibitors, which were originally developed for diabetes management, have shown promise in reducing cardiovascular events and heart failure in IHD patients. Large-scale clinical trials have been conducted to assess the safety and effectiveness of IHD drugs. These trials not only confirm the benefits of existing medications but also lead to the discovery of new drugs. For instance, trials like the EMPA-REG OUTCOME and DECLARE-TIMI 58 have provided valuable data on SGLT2 inhibitors and their impact on cardiovascular outcomes. Advances in genomics and molecular profiling have allowed for more personalized treatment approaches. Genetic and molecular testing can help identify specific risk factors and tailor treatment regimens to individual patient profiles.

In May 2024, Akums Drugs and Pharmaceuticals launched a new fixed-dose combination (FDC) medication for resistant hypertension, marking a significant advancement in the drug development landscape, particularly in the ischemic heart disease (IHD) market. The Amlodipine, Telmisartan, and Metoprolol (ER) film-coated tablets combine three well-established medications into one pill, streamlining blood pressure management. Approved by the DCGI, this combination features a calcium channel blocker, an angiotensin II receptor antagonist, and a beta-blocker, targeting multiple mechanisms of blood pressure regulation. As hypertension is a key risk factor for IHD, this FDC offers an innovative approach to addressing both conditions. The single-pill format is designed to improve patient adherence, making it a more effective and convenient treatment option for IHD patients, further driving innovation in the IHD drugs market.

There has been a growing interest in combination therapies, where multiple drugs with different mechanisms of action are used together. This approach can offer enhanced benefits and reduce the risk of IHD progression. Emerging therapies, such as biologics and gene-based treatments, are being explored. These cutting-edge approaches have the potential to address IHD at the genetic or molecular level, providing more targeted and effective treatment. Advances in precision medicine are helping to identify IHD patients who are more likely to respond to specific drugs or interventions, optimizing treatment outcomes. Inflammation is recognized as a contributor to atherosclerosis and IHD. The development of anti-inflammatory drugs, such as anti-interleukin-1 beta (IL-1B) monoclonal antibodies, is under investigation to reduce inflammation and cardiovascular risk. The integration of telemedicine and digital health solutions has improved the remote monitoring and management of IHD patients. This not only enhances patient care but also allows for real-time data collection and analysis to inform treatment decisions. The introduction of biosimilars for certain cardiovascular drugs can provide cost-effective alternatives, increasing access to IHD treatments. Regulatory agencies like the U.S. Food and Drug Administration (FDA) have implemented expedited approval pathways for innovative IHD drugs, accelerating their availability to patients. This factor will help in the development of the Global Ischemic Heart Disease (IHD) Drugs Market.

Increasing Early Diagnosis and Intervention

Early diagnosis of IHD allows for timely medical intervention, which can help prevent or minimize complications. Identifying the condition in its early stages can lead to more effective treatment, reducing the risk of heart attacks, heart failure, and other severe cardiac events. Starting treatment at an early stage of IHD can significantly improve patient outcomes. Medications, lifestyle modifications, and other interventions initiated in the early phases of the disease can slow its progression and improve the patient's quality of life. Ischemic heart disease, if left untreated, can lead to heart muscle damage. Early intervention with IHD drugs can prevent further damage and, in some cases, help the heart muscle recover. Early diagnosis and treatment can reduce the need for hospitalization and emergency medical interventions, which are often costlier and have a more significant impact on the patient's overall health and quality of life. The timely initiation of IHD drugs and treatment regimens can reduce mortality rates associated with the disease. Medications that control blood pressure, cholesterol levels, and reduce the risk of blood clots can be lifesaving when administered early.

Early diagnosis and intervention provide an opportunity for healthcare professionals to educate patients about the importance of adhering to their prescribed medication regimens. When patients understand the benefits and importance of their treatment, they are more likely to comply with it. Early diagnosis allows for the customization of treatment plans based on the patient's specific risk factors, medical history, and needs. This personalized approach can lead to more effective drug choices and treatment strategies. Early diagnosis often prompts lifestyle changes, such as improved diet and increased physical activity, which can complement drug therapy and reduce the progression of IHD. Early diagnosis provides an opportunity to identify and address risk factors for IHD, such as high blood pressure, high cholesterol, and diabetes. Managing these risk factors through medication and lifestyle changes is key to preventing IHD progression. Timely diagnosis and intervention can lead to cost savings for both the patient and the healthcare system by reducing the need for costly emergency care, surgeries, and long-term hospitalization. This factor will pace up the demand of the Global Ischemic Heart Disease (IHD) Drugs Market.

Rising Aging Population

Ischemic heart disease becomes more prevalent with advancing age. Older individuals are at a higher risk of developing IHD due to the cumulative effects of risk factors like atherosclerosis, hypertension, and diabetes. As the population ages, the overall incidence of IHD rises. This means that a larger proportion of the population needs IHD drugs for prevention and management. Aging is often accompanied by the presence of other medical conditions, such as diabetes, high blood pressure, and high cholesterol, which are risk factors for IHD. Consequently, a significant portion of the elderly population may require IHD drugs to address these comorbidities. According to the World Health Organization (WHO), by 2030, one in six people globally will be aged 60 or older, with the population of those aged 60 and above rising from 1 billion in 2020 to 1.4 billion. By 2050, this figure is expected to double, reaching 2.1 billion, while the number of individuals aged 80 and older is projected to triple, reaching 426 million. This demographic shift is expected to drive significant growth in the ischemic heart disease (IHD) drugs market, as aging populations are more prone to cardiovascular conditions. As the prevalence of IHD increases with age, the demand for innovative treatments, preventive measures, and management solutions for heart disease will likely surge, presenting growth opportunities for companies in the cardiovascular pharmaceutical sector.

Older individuals who have already experienced cardiac events like heart attacks or angina may require IHD drugs for secondary prevention. This population benefits from medications that reduce the risk of recurrent events. Older patients often have complex medical profiles, with multiple chronic conditions. This necessitates a combination of medications, including IHD drugs, to manage their health effectively. IHD is a chronic condition that requires ongoing management. The aging population is likely to require long-term drug therapy to control the disease, reduce symptoms, and prevent complications. The field of geriatric cardiology focuses on the unique cardiovascular needs of the elderly. This specialty has led to a better understanding of how to manage IHD in older patients, driving the demand for age-specific drug regimens. Advances in healthcare and medical treatments have increased life expectancy. As people live longer, there is a growing need for IHD drugs to maintain heart health in the later stages of life. Older individuals may seek medical care and drug therapy to prevent the onset of IHD, especially if they have risk factors. This proactive approach to heart health contributes to the demand for preventive IHD drugs. The economic burden of treating IHD in the elderly population, including hospitalizations and emergency care, incentivizes healthcare systems to focus on preventive strategies and pharmacological management, further driving the demand for IHD drugs. This factor will accelerate the demand of the Global Ischemic Heart Disease (IHD) Drugs Market.

Key Market Challenges

Drug Pricing and Affordability

Some IHD drugs can be expensive, particularly newer or patented medications. These costs can be a barrier to access for patients, particularly those without comprehensive health insurance. IHD is a chronic condition that often requires long-term drug therapy. The cumulative cost of medications over time can be a substantial financial burden for patients. Many individuals with IHD require multiple medications to manage the condition effectively. The cost of multiple drugs can add up, making it more challenging for patients to afford their prescribed regimen. Health insurance plans may have restrictions on coverage for certain medications, leading to out-of-pocket expenses for patients. High deductibles, co-pays, and co-insurance can contribute to the financial burden. Elderly patients with IHD who are covered under Medicare Part D may face the "doughnut hole" coverage gap, where drug costs significantly increase before catastrophic coverage kicks in. Some IHD drugs may not have generic alternatives available, which can keep the cost of treatment higher, especially for those without insurance or with high co-pays. The pharmaceutical industry sometimes raises drug prices, which can have a direct impact on the affordability of IHD medications for both patients and healthcare systems. Drug pricing can vary significantly between countries, resulting in different levels of affordability for the same medications. This can lead to disparities in access to IHD drugs worldwide.

Generic Competition

When generic versions of branded IHD drugs become available, they typically come at significantly lower prices. This can erode the market share and profitability of the original branded drugs. Branded drugs that have lost patent protection face competition from generic versions. This can result in a shift of market share from branded to generic drugs, impacting the revenue of pharmaceutical companies. When the patents on branded IHD drugs expire, generic manufacturers can legally produce and sell equivalent medications, which can lead to a rapid decrease in the price of the drug. Generic competition can benefit patients by offering more affordable alternatives. This is particularly important for individuals with IHD who require long-term medication regimens. Generic competition can exert pressure on pharmaceutical companies to develop new, innovative drugs or explore other revenue streams. They may invest in research and development to create next-generation IHD medications. While generic drugs can be cost-effective, changes in drug appearance (e.g., color, shape, and packaging) when switching from a brand-name drug to a generic can affect patient adherence if patients become confused or concerned about the change. Generic drugs are required to meet regulatory standards for safety and efficacy, ensuring they are therapeutically equivalent to their brand-name counterparts. However, concerns about the quality of generic drugs can impact patient trust and acceptance.

Key Market Trends

Increased Use of Statins

Statins have a well-documented track record of effectively lowering LDL cholesterol levels, a major risk factor for atherosclerosis and IHD. Lowering LDL cholesterol reduces the risk of coronary artery disease and related events. Statins are often prescribed as a preventive measure to individuals with risk factors for IHD, such as high cholesterol levels, diabetes, or a family history of heart disease. This proactive approach helps in preventing IHD from developing in the first place. Statins are commonly used in individuals with coexisting conditions such as hypertension and diabetes, which often occur alongside IHD. They help address multiple risk factors simultaneously. Statins are used for both primary prevention (preventing IHD in individuals at risk but without prior cardiac events) and secondary prevention (reducing the risk of recurrent events in individuals who have already experienced heart attacks or other cardiovascular events). In July 2024, the Cardiological Society of India (CSI) introduced new guidelines for managing dyslipidemia. These updated guidelines recommend non-fasting lipid measurements for risk assessment and treatment, moving away from the traditional fasting approach. The guidelines also emphasize the use of statins, non-statin drugs, and injectable lipid-lowering agents such as PCSK9 inhibitors and Inclisiran, with a particular focus on high-intensity statin therapy or combination therapy to achieve more aggressive lipid-lowering targets. This shift in treatment strategy is expected to contribute to the increasing use of statins in the ischemic heart disease (IHD) drugs market. As guidelines increasingly recommend higher-intensity statin therapies and combination approaches, the demand for these medications is likely to rise, particularly among patients with dyslipidemia, a key risk factor for IHD. This trend highlights the growing market for IHD drugs, as statins remain a cornerstone of cardiovascular disease prevention and management. Medical guidelines and recommendations strongly support the use of statins for the management of IHD and cardiovascular risk reduction. Guidelines from organizations like the American College of Cardiology and American Heart Association provide clear criteria for statin therapy. Many statins have become available as generic medications, making them more affordable and accessible for a broader patient population. This has contributed to their increased use. Statins are often used in combination with other drugs, such as antiplatelet agents and antihypertensive medications, to optimize IHD management and reduce the risk of cardiovascular events. Statins are typically well-tolerated by patients, which promotes adherence to treatment plans. Consistent use of statins is crucial for their effectiveness in reducing cardiovascular risk.

Segmental Insights

Disease Type Insights

Based on Disease Class, the Angina Pectoris emerged as the fastest growing segment in the global market for Ischemic Heart Disease (IHD) Drugs during the forecast period. Angina pectoris, commonly associated with coronary artery disease (CAD), is becoming increasingly prevalent due to factors such as an aging population, unhealthy lifestyle choices, and the rising occurrence of risk factors like hypertension, obesity, and diabetes. As these risk factors continue to grow worldwide, the number of angina cases is also on the rise, driving demand for effective treatments. There is a heightened focus on early detection and diagnosis of cardiovascular conditions, including angina, leading to more individuals being diagnosed at earlier stages of CAD. This creates a greater need for efficient management strategies to control symptoms and prevent disease progression. The development of new medications and therapies aimed at improving blood flow, alleviating symptoms, and reducing the frequency of angina episodes has expanded treatment options. Medications such as nitrates, beta-blockers, calcium channel blockers, and newer therapies like PCSK9 inhibitors and anti-anginal drugs are contributing to the growing demand in this segment. Given the significant impact of angina on quality of life, there is a strong emphasis on improving symptom management, which is driving investment in drug development. Furthermore, as the global population ages, the prevalence of age-related cardiovascular conditions, including angina, is increasing, making effective angina treatments even more crucial in managing overall heart health for older adults.

Drug Class Insights

Based on Drug Class, ACE Inhibitors emerged as the dominating segment in the global market for Ischemic Heart Disease (IHD) Drugs in 2024. ACE (Angiotensin-Converting Enzyme) Inhibitors have a well-established track record for effectively managing various cardiovascular conditions, including IHD. They are known to reduce blood pressure, improve heart function, and enhance outcomes for individuals with heart disease. ACE Inhibitors are widely prescribed not only for IHD but also for other heart-related conditions like hypertension and heart failure. This broad applicability contributes to their large market share. Medical guidelines and recommendations often Favor the use of ACE Inhibitors as a first-line treatment for patients with IHD. This helps drive their widespread adoption. ACE Inhibitors have been extensively studied in clinical trials, demonstrating their ability to reduce the risk of heart-related events and improve the quality of life for IHD patients. ACE Inhibitors are often considered cost-effective, making them a preferred choice for both healthcare providers and patients. Many ACE Inhibitors have been in use for several decades, and their safety and efficacy have been well-established over time. This history builds trust among healthcare professionals and patients.

Regional Insights

Based on Region, North America emerged as the dominant region in the Global Ischemic Heart Disease (IHD) Drugs Market in 2024. The aging population in North America plays a key role in the growth of the ischemic heart disease (IHD) drugs market. According to the National Council on Aging (NCOA), in 2022, there were 57.8 million adults aged 65 and older in the U.S., comprising 31.9 million women and 25.9 million men. As individuals age, their risk of developing cardiovascular diseases, including IHD, increases, driving up demand for medications to manage conditions like angina and myocardial infarction. North America benefits from a well-established healthcare system and advanced medical infrastructure, which ensures broad access to modern IHD treatments and supports early diagnosis and effective disease management. The region is also home to some of the largest pharmaceutical markets globally, with substantial investments in research and development, positioning it as a hub for the development and commercialization of new IHD therapies, including statins, anti-anginal drugs, and innovative treatments like PCSK9 inhibitors. Additionally, government initiatives in the U.S. and Canada heavily invest in public health programs targeting cardiovascular diseases, while public and private insurance systems facilitate greater accessibility to these drugs. North America's leadership in clinical trials and medical research further fosters innovation and early access to new therapies. Together, these factors position North America as the dominant player in the global IHD drugs market, significantly contributing to its growth and expansion.

Key Market Players

Bayer AG
Eli Lilly and Company
Novartis International AG
Pfizer, Inc.
Sanofi S.A.
Actelion Pharmaceuticals Ltd.
Baxter International Inc.
Boehringer Ingelheim International GmbH
Bristol-Myers Squibb Company
F. Hoffmann-La Roche AG

Report Scope:

In this report, the Global Ischemic Heart Disease (IHD) Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Ischemic Heart Disease (IHD) Drugs Market, By Disease Class:

Angina Pectoris
Myocardial Infarction

Ischemic Heart Disease (IHD) Drugs Market, By Drug Class:

Anti-Dyslipidemic Drugs
Calcium Channel Blockers
Beta-Blockers
ACE Inhibitors
ARBs
Vasodilators
Antithrombotic Agents

Ischemic Heart Disease (IHD) Drugs Market, By region:

North America
- United States
- Canada
- Mexico
Asia Pacific
- China
- India
- South Korea
- Australia
- Japan
Europe
- Germany
- France
- United Kingdom
- Spain
- Italy
South America
- Brazil
- Argentina
- Colombia
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Ischemic Heart Disease (IHD) Drugs Market.

Available Customizations:

Global Ischemic Heart Disease (IHD) Drugs Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Ischemic Heart Disease (IHD) Drugs Market Outlook

5.1. Market Size & Forecast
- 5.1.1. By Value
5.2. Market Share & Forecast
- 5.2.1. By Disease Class (Angina Pectoris, Myocardial Infarction)
- 5.2.2. By Drug Class (Anti-Dyslipidemic Drugs, Calcium Channel Blockers, Beta-Blockers, ACE Inhibitors, ARBs, Vasodilators, Antithrombotic Agents)
- 5.2.3. By Region
- 5.2.4. By Company (2024)
5.3. Market Map

6. Asia Pacific Ischemic Heart Disease (IHD) Drugs Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Disease Class
- 6.2.2. By Drug Class
- 6.2.3. By Country
6.3. Asia Pacific: Country Analysis
- 6.3.1. China Ischemic Heart Disease (IHD) Drugs Market Outlook
  - 6.3.1.1. Market Size & Forecast
    - 6.3.1.1.1. By Value
  - 6.3.1.2. Market Share & Forecast
    - 6.3.1.2.1. By Disease Class
    - 6.3.1.2.2. By Drug Class
- 6.3.2. India Ischemic Heart Disease (IHD) Drugs Market Outlook
  - 6.3.2.1. Market Size & Forecast
    - 6.3.2.1.1. By Value
  - 6.3.2.2. Market Share & Forecast
    - 6.3.2.2.1. By Disease Class
    - 6.3.2.2.2. By Drug Class
- 6.3.3. Australia Ischemic Heart Disease (IHD) Drugs Market Outlook
  - 6.3.3.1. Market Size & Forecast
    - 6.3.3.1.1. By Value
  - 6.3.3.2. Market Share & Forecast
    - 6.3.3.2.1. By Disease Class
    - 6.3.3.2.2. By Drug Class
- 6.3.4. Japan Ischemic Heart Disease (IHD) Drugs Market Outlook
  - 6.3.4.1. Market Size & Forecast
    - 6.3.4.1.1. By Value
  - 6.3.4.2. Market Share & Forecast
    - 6.3.4.2.1. By Disease Class
    - 6.3.4.2.2. By Drug Class
- 6.3.5. South Korea Ischemic Heart Disease (IHD) Drugs Market Outlook
  - 6.3.5.1. Market Size & Forecast
    - 6.3.5.1.1. By Value
  - 6.3.5.2. Market Share & Forecast
    - 6.3.5.2.1. By Disease Class
    - 6.3.5.2.2. By Drug Class

7. Europe Ischemic Heart Disease (IHD) Drugs Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Disease Class
- 7.2.2. By Drug Class
- 7.2.3. By Country
7.3. Europe: Country Analysis
- 7.3.1. France Ischemic Heart Disease (IHD) Drugs Market Outlook
  - 7.3.1.1. Market Size & Forecast
    - 7.3.1.1.1. By Value
  - 7.3.1.2. Market Share & Forecast
    - 7.3.1.2.1. By Disease Class
    - 7.3.1.2.2. By Drug Class
- 7.3.2. Germany Ischemic Heart Disease (IHD) Drugs Market Outlook
  - 7.3.2.1. Market Size & Forecast
    - 7.3.2.1.1. By Value
  - 7.3.2.2. Market Share & Forecast
    - 7.3.2.2.1. By Disease Class
    - 7.3.2.2.2. By Drug Class
- 7.3.3. Spain Ischemic Heart Disease (IHD) Drugs Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecast
    - 7.3.3.2.1. By Disease Class
    - 7.3.3.2.2. By Drug Class
- 7.3.4. Italy Ischemic Heart Disease (IHD) Drugs Market Outlook
  - 7.3.4.1. Market Size & Forecast
    - 7.3.4.1.1. By Value
  - 7.3.4.2. Market Share & Forecast
    - 7.3.4.2.1. By Disease Class
    - 7.3.4.2.2. By Drug Class
- 7.3.5. United Kingdom Ischemic Heart Disease (IHD) Drugs Market Outlook
  - 7.3.5.1. Market Size & Forecast
    - 7.3.5.1.1. By Value
  - 7.3.5.2. Market Share & Forecast
    - 7.3.5.2.1. By Disease Class
    - 7.3.5.2.2. By Drug Class

8. North America Ischemic Heart Disease (IHD) Drugs Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Disease Class
- 8.2.2. By Drug Class
- 8.2.3. By Country
8.3. North America: Country Analysis
- 8.3.1. United States Ischemic Heart Disease (IHD) Drugs Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Disease Class
    - 8.3.1.2.2. By Drug Class
- 8.3.2. Mexico Ischemic Heart Disease (IHD) Drugs Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Disease Class
    - 8.3.2.2.2. By Drug Class
- 8.3.3. Canada Ischemic Heart Disease (IHD) Drugs Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Disease Class
    - 8.3.3.2.2. By Drug Class

9. South America Ischemic Heart Disease (IHD) Drugs Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Disease Class
- 9.2.2. By Drug Class
- 9.2.3. By Country
9.3. South America: Country Analysis
- 9.3.1. Brazil Ischemic Heart Disease (IHD) Drugs Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Disease Class
    - 9.3.1.2.2. By Drug Class
- 9.3.2. Argentina Ischemic Heart Disease (IHD) Drugs Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Disease Class
    - 9.3.2.2.2. By Drug Class
- 9.3.3. Colombia Ischemic Heart Disease (IHD) Drugs Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Disease Class
    - 9.3.3.2.2. By Drug Class

10. Middle East and Africa Ischemic Heart Disease (IHD) Drugs Market Outlook

10.1. Market Size & Forecast
- 10.1.1. By Value
10.2. Market Share & Forecast
- 10.2.1. By Disease Class
- 10.2.2. By Drug Class
- 10.2.3. By Country
10.3. MEA: Country Analysis
- 10.3.1. South Africa Ischemic Heart Disease (IHD) Drugs Market Outlook
  - 10.3.1.1. Market Size & Forecast
    - 10.3.1.1.1. By Value
  - 10.3.1.2. Market Share & Forecast
    - 10.3.1.2.1. By Disease Class
    - 10.3.1.2.2. By Drug Class
- 10.3.2. Saudi Arabia Ischemic Heart Disease (IHD) Drugs Market Outlook
  - 10.3.2.1. Market Size & Forecast
    - 10.3.2.1.1. By Value
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By Disease Class
    - 10.3.2.2.2. By Drug Class
- 10.3.3. UAE Ischemic Heart Disease (IHD) Drugs Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Disease Class
    - 10.3.3.2.2. By Drug Class

11. Market Dynamics

11.1. Drivers
11.2. Challenges

12. Market Trends & Developments

12.1. Recent Developments
12.2. Product Launches
12.3. Mergers & Acquisitions

13. Global Ischemic Heart Disease (IHD) Drugs Market: SWOT Analysis

14. Porter's Five Forces Analysis

14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Product

15. PESTLE Analysis

16. Competitive Landscape

16.1. Bayer AG
- 16.1.1. Business Overview
- 16.1.2. Company Snapshot
- 16.1.3. Products & Services
- 16.1.4. Financials (In case of listed companies)
- 16.1.5. Recent Developments
- 16.1.6. SWOT Analysis
16.2. Eli Lilly and Company
- 16.2.1. Business Overview
- 16.2.2. Company Snapshot
- 16.2.3. Products & Services
- 16.2.4. Financials (In case of listed companies)
- 16.2.5. Recent Developments
- 16.2.6. SWOT Analysis
16.3. Novartis International AG
- 16.3.1. Business Overview
- 16.3.2. Company Snapshot
- 16.3.3. Products & Services
- 16.3.4. Financials (In case of listed companies)
- 16.3.5. Recent Developments
- 16.3.6. SWOT Analysis
16.4. Pfizer, Inc.
- 16.4.1. Business Overview
- 16.4.2. Company Snapshot
- 16.4.3. Products & Services
- 16.4.4. Financials (In case of listed companies)
- 16.4.5. Recent Developments
- 16.4.6. SWOT Analysis
16.5. Sanofi S.A
- 16.5.1. Business Overview
- 16.5.2. Company Snapshot
- 16.5.3. Products & Services
- 16.5.4. Financials (In case of listed companies)
- 16.5.5. Recent Developments
- 16.5.6. SWOT Analysis
16.6. Actelion Pharmaceuticals Ltd.
- 16.6.1. Business Overview
- 16.6.2. Company Snapshot
- 16.6.3. Products & Services
- 16.6.4. Financials (In case of listed companies)
- 16.6.5. Recent Developments
- 16.6.6. SWOT Analysis
16.7. Baxter International Inc
- 16.7.1. Business Overview
- 16.7.2. Company Snapshot
- 16.7.3. Products & Services
- 16.7.4. Financials (In case of listed companies)
- 16.7.5. Recent Developments
- 16.7.6. SWOT Analysis
16.8. Boehringer Ingelheim International GmbH
- 16.8.1. Business Overview
- 16.8.2. Company Snapshot
- 16.8.3. Products & Services
- 16.8.4. Financials (In case of listed companies)
- 16.8.5. Recent Developments
- 16.8.6. SWOT Analysis
16.9. Bristol-Myers Squibb Company
- 16.9.1. Business Overview
- 16.9.2. Company Snapshot
- 16.9.3. Products & Services
- 16.9.4. Financials (In case of listed companies)
- 16.9.5. Recent Developments
- 16.9.6. SWOT Analysis
16.10. F. Hoffmann-La Roche AG
- 16.10.1. Business Overview
- 16.10.2. Company Snapshot
- 16.10.3. Products & Services
- 16.10.4. Financials (In case of listed companies)
- 16.10.5. Recent Developments
- 16.10.6. SWOT Analysis